Cornelia Schuster's picture

Cornelia Schuster

Postdoctoral Fellow
  • E-mailcornelia.schuster@uib.no
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2021). Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up. International Journal of Cancer. 100-111.
  • Show author(s) (2019). ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab. Scientific Reports. 1-15.
  • Show author(s) (2019). Prognostic value of uPAR expression and angiogenesis in primary and metastatic melanoma. PLOS ONE. 1-18.
  • Show author(s) (2019). Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy. The journal of pathology. Clinical research. 53-62.
  • Show author(s) (2016). Expression of Heat Shock Protein 27 in melanoma metastases is associated with overall response to bevacizumab monotherapy: Analyses of predictive markers in a clinical phase II study. PLOS ONE.
  • Show author(s) (2012). Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLOS ONE. 8 pages.
Doctoral dissertation
  • Show author(s) (2016). Investigation of predictive markers in patients with metastatic melanoma treated with bevacizumab.
Academic chapter/article/Conference paper
  • Show author(s) (2017). The Tumor Microenvironment in Cutaneous Melanoma: Friend or Foe. 26 pages.
  • Show author(s) (2018). Update on the randomised phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma. Annals of Oncology. viii452-viii452.

More information in national current research information system (CRIStin)